Natco Pharma Limited — PPTs, 28-05-2025: Investor Presentation

1. Financial Highlights:

Total revenue for Q4FY25 stood at INR 1,287.3 Cr with pharma export formulations contributing INR 1,052.5 Cr and domestic formulations at INR 99.4 Cr. FY25 revenue reached INR 4,784 Cr, driven by INR 3,760 Cr from exports and INR 400 Cr from domestic formulations. EBITDA for Q4 grew to INR 614.4 Cr (47.7% margin) from INR 539.3 Cr a year ago, with FY25 EBITDA rising to INR 2,550.5 Cr (53.3% margin) versus INR 1,879.5 Cr. PAT was strong at INR 406 Cr (31.5% margin) for the quarter and INR 1,883.4 Cr (39.4% margin) for FY25. The balance sheet reflected a one-time INR 50 Cr impairment related to Crop Health Sciences.

2. Strategic Initiatives & Growth Drivers:

NATCO is progressing specialty generics with multiple recent ANDA approvals including Bosentan and Everolimus oral suspensions. Investments exceeding INR 100 Cr in biotech companies focusing on xenotransplantation, CAR-T, and regenerative medicine fuel growth in oncology and rare diseases. This positions NATCO at the forefront of next-gen cell and gene therapy innovation.

3. Business Developments:

The company is advancing 20+ Para IV exclusivity filings in the US, including several first-to-file opportunities, highlighting a robust generic pipeline. Clinical trials for NRC-2694, targeting head and neck cancer, are ongoing in both US and India. Licensing and profit-sharing arrangements continue to support export formulation revenues.

4. Market Position & Competitive Advantage:

NATCO maintains leadership in specialty generics and oncology with expanding margins and a diversified portfolio. Its entry into differentiated biologics and cell therapies provides scale advantages and deepens pipeline resilience, strengthening its foothold in domestic and international markets.

5. Investor Implications:

Strong revenue and margin expansion combined with strategic biotech investments indicate positive growth potential, particularly from specialty complex generics and innovative therapies. Execution on pipeline filings and clinical programs will be critical. The impairment in Crop Health Sciences suggests some execution risk in diversification, but overall, NATCO shows solid momentum with a clear innovation focus.